MannKind Corp. said the U.S. Food and Drug Administration has cleared the Valencia-based drug developer to begin human testing for one of its cancer drugs.

The company said on Monday it can now begin early-stage clinical trials on MKC1106-PP to test its safety and the ability of patients with solid tumors to tolerate it. Enrollment of participants is expected by the end of this year.

The company is in late-stage trials on its lead product, an inhaleable insulin system called Technosphere.

Mannkind’s shares were off 9 cents in afternoon trading on Nasdaq to $17.35.